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Endothelial cell damage has been reported to be associated with noninfectious transplant-related compli-
cations after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Among these, noninfectious
transplant-related complications with endothelial cell damage (TRC-EC) include sinusoidal occlusive syn-
drome, transplant-associated microangiopathy, intestinal transplant-associated microangiopathy, capillary
leak syndrome, idiopathic pneumonia syndrome, and diffuse alveolar hemorrhage. Because angiopoietin-2
(ANG2) plays an essential role in the endothelial cell damage of various inﬂammatory disorders, we hy-
pothesized that ANG2 may also play a critical role in TRC-EC. We retrospectively estimated the incidence of
TRC-EC and evaluated the association with ANG2 level at transplant. We studied 153 consecutive adult
patients who underwent allo-HSCT at our institution between 2000 and 2012. Median patient age was
49 years (range, 16 to 68 years). With a median follow-up of 55 months, 3-year overall survival for all patients
was 55%. The incidence of TRC-EC at day 100 was signiﬁcantly higher in the high-ANG2 group (2000 pg/mL;
n ¼ 36) than in the low-ANG2 group (<2000 pg/mL; n ¼ 117) (70% [95% conﬁdence interval {CI}, 55% to 84%]
versus 16% [95% CI, 11% to 24%]; P < .001). Multivariate analysis revealed that high ANG2 level at transplant
was independently associated with higher risk of TRC-EC (hazard ratio, 6.01; 95% CI, 3.16 to 11.43; P < .001)
and shorter overall survival (hazard ratio, 2.23; 95% CI, 1.66 to 4.48; P ¼ .002). These results suggest that ANG2
level at transplant may be a useful marker for predicting the risk of TRC-EC after allo-HSCT. Prospective
studies are warranted to validate our results.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a curative procedure for a subset of patients with
hematologic malignancies. However, allo-HSCT is still asso-
ciated with high treatment-related mortality due to severe
infections and fatal noninfectious complications. Although
acute graft-versus-host disease (aGVHD) is a major compli-
cation early after allo-HSCT, patients often experience other
serious complications, such as sinusoidal occlusive syndrome
(SOS), transplant-associated microangiopathy (TAM), intes-
tinal TAM (iTAM), capillary leak syndrome (CLS), hemopha-
gocytic syndrome, idiopathic pneumonia syndrome (IPS),dgments on page 1340.
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14.04.030diffuse alveolar hemorrhage (DAH), and engraftment
syndrome.
Endothelial cell damage is suggested to have a critical role
in the pathogenesis of noninfectious complications after allo-
HSCT and is presumed to cause inadequate capillary blood
ﬂow and hypoxia, which may translate into life-threatening
end-organ damage. Among the noninfectious complica-
tions, SOS, TAM, iTAM, CLS, IPS, and DAH are considered to be
closely related to endothelial cell damage [1,2]. Thus, we
deﬁned these complications as transplant-related compli-
cations with endothelial cell damage (TRC-EC). Because of
the lack of effective treatment for TRC-EC, the prognosis of
patients with TRC-EC is markedly poor [3]. Identiﬁcation of
risk factors and biomarkers for TRC-EC may help to elucidate
the pathophysiology of this disorder and become the
fundamental clue for the future development of prevention
and management strategies.
Angiopoietin-2 (ANG2) is a ligand for the Tie2 (tyrosine
kinase with Ig-like loops and epidermal growth factorTransplantation.
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“unstable status” of damaged blood vessels [4]. ANG2 has
been shown to be up-regulated in systemic inﬂammation of a
variety of disease entities, including sepsis and systemic
lupus erythematosus [5-7]. Moreover, Luft et al. [8] has
shown that ANG2 is related to steroid-refractory aGVHD.
However, the role of ANG2 in TRC-EC has not been previously
evaluated.
In the early phase after allo-HSCT, ANG2 may also play an
essential role in promoting endothelial cell damage and
leading to the development of TRC-EC. Thus, we retrospec-
tively evaluated the clinical and prognostic value of ANG2 at
transplantation in patients who underwent allo-HSCT in our
institution.
METHODS
Patients
Patients who underwent allo-HSCT at Konan Kosei Hospital between
January 2000 and December 2012 and had available blood samples between
day e5 and day 3 of the transplantation date were included in this study.
Patients who had undergone any prior transplantation were excluded. A
total of 153 patients was analyzed. Pretransplant patient characteristics
were collected to evaluate the risk factors for TRC-EC.
High-risk disease included acute leukemia and malignant lymphoma
not in remission and myelodysplastic syndrome in refractory anemia with
excess blasts-II (RAEB-II) according to 2008 WHO classiﬁcation [9], whereas
standard risk included others that do not meet the criteria deﬁned for high-
risk disease. Reduced-intensity conditioning (RIC) and myeloablative con-
ditioning regimens were deﬁned according to the proposed deﬁnition from
the Center for International Blood and Marrow Transplant Research work-
shop, except for the melphalan dose [10]. In the present study, RIC was
deﬁned as including a melphalan dose of 140 mg/m2.
Written informed consent according to the Declaration of Helsinki was
obtained for all eligible patients. Our local Ethics Committee approved the
sample and data collection procedures.
Deﬁnition of Complications
TRC-EC was deﬁned as SOS, systemic TAM, iTAM, CLS, IPS, and DAH
within day 100. If a patient experienced multiple TRC-EC episodes, we
analyzed the TRC-EC episode that developed “ﬁrst” during the post-
transplant course.
SOS was diagnosed according to the Seattle Criteria [11], IPS by National
Heart, Lung, and Blood Institute working group criteria [12], and DAH by
previously reported criteria [13]. CLS was deﬁned by previously reported
criteria [14]. Brieﬂy, CLS was diagnosed clinically by the presence of rapid
weight gain (>3% within 24 hours) without hyperbilirubinemia and
generalized ﬂuid retention that characteristically does not respond to
furosemide treatment. TAM was deﬁned as grade II or more thrombotic
microangiopathy by Blood and Marrow Transplant Clinical Trials Network
(BMT-CTN) criteria [15].
iTAM, a variant of TAM,was deﬁned pathologically according to a previous
report [16]. In brief, the typical features of iTAM are development of abdom-
inal pain and severe and bloody diarrhea with characteristic histopathology
by means of colonoscopic biopsy. Biopsy shows the presence of swollen
endothelial cells and denuded endothelial cells with ischemic changes, such
as noninﬂammatory crypt degeneration, wedge-shaped segmental injury
and interstitial edema, with hemorrhage or fragmented RBCs [16].
aGVHD was diagnosed and graded according to reported criteria [17,18].
In this study, pre-engraftment immune reaction, a post-transplant compli-
cation that is similar to hyperacute GVHD, was also analyzed and graded as
aGVHD [19].
Data Collection and Diagnosis of Complications
In this study, post-transplant complications were mainly diagnosed in
real time. The pathologic diagnosis of iTAM was conﬁrmed by an indepen-
dent pathologist, and all diagnoses of complications were conﬁrmed ac-
cording to the strict deﬁnitions by reviewing all the medical charts up to day
100 after transplant. Assessors were blinded to the results of the ANG2 levels.
Management of Patients
Standard patient care was performed. For the patients with TAM, fresh
frozen plasma infusion, plasma exchange, restriction of platelet transfusion,
or reduction of calcineurin inhibitors were used. No predetermined protocol
was applied for severe aGVHD.Plasma Samples and ELISA
Patient blood samples at transplant (between day e5 and day 3 of the
transplantation date) were collected, and plasma was isolated by centrifu-
gation and frozen at e30C until use. Plasma ANG2 levels were measured by
an angiopoietin-2 ELISA kit (R&D Systems, Minneapolis, MN). We set the
cut-off value of 2000 pg/mL for ANG2 at transplantation for all analyses. The
cut-off value for ANG2was chosen based on the upper quartile level of ANG2
in our patient cohort because the incidence of TRC-EC was markedly higher
in the fourth quartile than in the other three quartiles. In this study, we refer
to “ANG2 at transplantation” simply as “ANG2” unless otherwise stated.
Statistical Analysis
Evaluated endpoints included cumulative incidence of TRC-EC, aGVHD,
overall survival (OS), nonrelapse mortality (NRM), and relapse. Incidence of
TRC-EC was deﬁned as the time from transplant to the onset of the ﬁrst TRC-
EC episode. OS was calculated as the time from transplant to death from any
cause, whereas NRM was calculated as the time from transplant to death
from any cause except relapse. For the analysis of relapse, 147 patients with
malignant disease were included and 6 patients with aplastic anemia were
excluded from analysis. Time to relapse was calculated as the time from
transplant to the recurrence of underlying hematologic malignant diseases.
For those who never achieved complete remission after allo-HSCT, day 1 of
transplantation was designated as date of relapse.
Mann-Whitney’s U test and Fisher exact tests were used for the
descriptive statistical analyses on continuous and categorical data. Incidence
of TRC-EC, aGVHD, OS, NRM, and relapse were calculated using the Kaplan-
Meier methods and compared between 2 groups by the log-rank test. For
relapse, death without relapse was the competing event.
Logistic regression models were used to evaluate the association of
pretransplant characteristics with higher ANG2 levels at transplant (>2000
pg/mL). The results with P < .05 were considered to be statistically
signiﬁcant.
Univariate and multivariate analyses were performed with Cox pro-
portional hazards regression models to identify potential independent risk
factors for incidence of TRC-EC, OS, and NRM. Multivariate analyses were
performed to adjust the impact of categorized plasma ANG2 at day 0 (cut-
off, 2000 pg/mL) on occurrence of TRC-EC, OS, and NRM for the following
potential confounders: age (<50 versus 50), sex, disease risk (standard
versus high), disease type (acute myelogenous leukemia/myelodysplastic
syndrome versus other), bonemarrow blast count (10% versus>10%), HCT-
CI score (0 to 3 versus>3), donor type (related donor versus unrelated donor
versus cord blood), and conditioning regimen (RIC versus myeloablative
conditioning and the use of busulfan [BU], melphalan, or total body irradi-
ation [TBI]). Multivariate analysis was done by a stepwise method using
threshold values for removal from and addition to the model of P ¼ .10 and
P ¼ .05, respectively. Results were expressed as hazard ratios (HRs) or odds
ratios (ORs) and 95% conﬁdence intervals (CIs). All analyses were performed
in STATA version 13.0 (College Station, TX).
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. Median
patient age was 49 years (range, 16 to 68 years), median
follow-up duration was 55 months, and the ratio of women
to menwas 1:2. The primary disease was acute myelogenous
leukemia in 77, myelodysplastic syndrome/Chronic myelo-
monocytic leukemia (CMML) in 26, chronic myelogenous
leukemia in 7, acute lymphoblastic leukemia in 25, non-
Hodgkin lymphoma in 11, Severe aplastic anemia (SAA) in
6, and multiple myeloma in 1. The risk of disease was stan-
dard in 95 and high in 58 patients. Bonemarrow blast counts
exceeded 10% in 38 of 153 patients. Three cases with T cell
depletion (pretransplant antithymocyte globulin) were
included in the present study.
Details of the conditioning regimens are also shown in
Table 1. One-fourth of the patients (n ¼ 39) received RIC
regimen. Because the cases of each regimen are relatively
small, we focused on the dose of BU, melphalan, and TBI that
might have major impacts on TRC-EC. The conditioning
regimen included BU (>8 mg/kg) in 26, melphalan
(>100 mg/m2) in 52, and TBI (>6 Gy) in 82 patients.
The median ANG2 level at transplant was 1360 pg/mL
(range, 355 to 9860 pg/mL). As in Methods, we set a cut-off
Table 1
Patient Characteristics
Parameters Whole
Cohort
Low-ANG2
Group
(<2000
pg/mL)
High-ANG2
Group
(2000
pg/mL)
P
No. of patients 153 117 36
Age at transplantation .385
50 yr 85 65 20
>50 yr 68 52 16
Sex .545
Male 102 76 26
Female 51 41 10
Disease .313
AML/MDS 103 76 27
Other 50 41 9
Disease risk <.001
Standard 95 83 12
High 58 34 24
BM blast <.001
10% 115 99 16
>10% 38 18 20
HCT-CI .121
3 138 108 30
>3 15 9 6
Graft type .048
Matched 81 68 13
Mismatched 28 18 10
Cord blood 44 31 13
GVHD prophylaxis .841
Cycrosporine A 50 39 11
Tacrolimus 103 78 25
Conditioning intensity .827
RIC 39 29 10
MAC 114 88 26
Conditioning regimen 1
BU .042
8 mg/kg 127 93 34
>8 mg/kg 26 24 2
Melphalan .070
100 mg/m2 101 82 19
>100 mg/m2 52 35 17
TBI .343
6 Gy 71 57 14
>6 Gy 82 60 22
Conditioning regimen 2
RIC
Flu-CY-TBI 11 9 2
Flu-Mel  140 mg/m2 21 17 4
Flu-Mel-TBI 5 3 2
Other 2 0 2
MAC
CY-TBI 32 27 5
BU-CY 22 22 0
CA-CY-TBI 28 22 6
Mel-TBI 12 6 6
Flu-Mel > 140 mg/m2 8 6 2
Flu-Mel-TBI 5 3 2
Flu-BU 4 2 2
Other 3 0 3
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; BM, bone marrow; HCT-CI, Hematopoietic Cell Transplantation
Comorbidity Index; MAC, myeloablative conditioning; Flu, ﬂudarabine;
CY, cyclophosphamide; Mel, melphalan; CA, cytarabine.
Table 2
TRC-EC within 100 Days after Transplant
Diagnosis Number of Patients Median Day of Diagnosis
after Transplant (Range)
SOS 10 9.5 (3-44)
CLS 12 13.5 (6-38)
TAM 10 19 (11-36)
iTAM 11 26 (11-53)
IPS 1 18
For patients with multiple TRC-EC episodes, only the TRC-EC episode that
developed ﬁrst during the post-transplant course is assessed and shown in
the table.
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low- and high-ANG2 groups (n ¼ 117 and 36, respectively).
The high-ANG2 group included more patients with high-risk
disease (P < .001) and higher bone marrow blast counts
(P < .001). More patients in the high-ANG2 group received
transplantation fromHLAmismatched donors (P¼ .048). The
BU-containing regimen was used less (P ¼ .042) and
melphalan-containing regimen more (P ¼ .070) in the high-
ANG2 group.Association of ANG2 with TRC-EC
TRC-EC was observed in 44 patients (28%): SOS (n ¼ 10),
CLS (n ¼ 12), TAM/iTAM (n ¼ 21), and IPS (n ¼ 1) (Table 2).
These include 16 patients who also experienced grades III to
IV aGVHD in their post-transplant course. We experienced
no case with DAH as the TRC-EC episode that developed
“ﬁrst” during the post-transplant course. The cumulative
incidence of TRC-EC by day 100 was 28%. When the cumu-
lative incidence of TRC-EC was compared according to ANG2
levels at transplant, the incidence of TRC-EC at day 100 in the
high-ANG2 group was drastically higher than the low-ANG2
group (70% and 16%, respectively; P < .001; Figure 1A).
Univariate analysis revealed the melphalan-containing con-
ditioning regimen, HLA-mismatched donor, and high ANG2
level were signiﬁcantly associated with the incidence of
TRC-EC (Table 3). Multivariate analysis revealed that high
ANG2 level (HR, 6.01; 95% CI, 3.16 to 11.43; P < .001) and
HLA-mismatched donor (HR, 1.99; 95% CI, 1.05 to 3.76;
P ¼ .033) were independently associated with higher risk of
TRC-EC (Table 3).
The 1-year OS for patients who experienced TRC-EC
within 100 days after transplant was signiﬁcantly lower
than those without TRC-EC (43% and 75%, respectively;
P< .001; data not shown). Moreover, the 1-year NRM rate for
patients who experienced TRC-EC within 100 days after
transplant was also signiﬁcantly higher than those without
TRC-EC (47% and 5%, respectively; P < .001; data not shown).
These data suggest that the TRC-EC diagnosed in the present
study have an apparent impact on patients’ survival.
In the present study, the range of time for the measure-
ment of ANG2 at transplantation is relatively wide (from day
e5 to day 3) because of the weekly sample storage policy
during allo-HSCT at our institute. Because most of the con-
ditioning is given until day e2 and calcineurin inhibitors
start from daye1, we investigated the ANG2 value measured
from day e5 to e2 (n ¼ 49) and from day e1 to day 3
(n¼ 104) as separate cohorts for the incidence of TRC-EC. The
incidence of TRC-EC in the high-ANG2 group was signiﬁ-
cantly higher than the low-ANG2 group both in the daye5 to
e2 cohort (66% and 16%, respectively; P < .001; data not
shown) and the day e1 to day 3 cohort (77% and 18%,
respectively; P < .001; data not shown). These data indicate
that irrespective of the difference in the measurement time
within this range, ANG2 is associated with TRC-EC.
Association of ANG2 with Grades III to IV aGVHD
Grades III to IV aGVHD was observed in 25 patients (16%),
including 16 patients who also experienced TRC-EC in their
post-transplant course. The cumulative incidence of grades
III to IV aGVHD by day 100 was 16%. Contrary to the obser-
vation in TRC-EC, no signiﬁcant difference was observed in
the cumulative incidence of grades III to IV aGVHD at day 100
Figure 1. Incidence of (A) TRC-EC, (B) grades III to IV aGVHD, (C) NRM, and (D) OS by ANG2 levels at transplant.
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respectively; P ¼ .463; Figure 1B).Association of ANG2 with NRM
The 1-, 3-, and 5-year NRM rates were 19%, 23%, and 26%,
respectively. The 5-year NRM rate in the high-ANG2 group
was signiﬁcantly higher compared with the low-ANG2 group
(42% and 21%, respectively: P ¼ .003; Figure 1C).
High ANG2 was signiﬁcantly associated with NRM in the
univariate analysis (HR, 2.79; 95% CI, 1.39 to 5.60; P ¼ .004)
but not signiﬁcantly in the multivariate analysis (HR, 2.02;
95% CI, .94 to 4.30; P ¼ .068). With regard to these data, 5-
year relapse rate for the high-ANG2 group was signiﬁcantly
higher than the low-ANG2 group in univariate analyses
(35.1% and 19.1%, respectively: P ¼ .004).Association of ANG2 with OS
The 1-, 3-, and 5-year OS rate were 67%, 55%, and 53%,
respectively. The 5-year OS rate in the high-ANG2 group was
signiﬁcantly lower compared with the low-ANG2 group (30%
and 60%, respectively: P < .001; Figure 1D).
Univariate analyses revealed high disease risk, higher
bone marrow blast counts, melphalan-containing condi-
tioning regimen, HLA-mismatched donor, and high ANG2
level were signiﬁcantly associated with shorter OS (Table 3).
Multivariate analyses revealed high ANG2 level (HR, 2.23;
95% CI, 1.66 to 4.48; P ¼ .002) was independently associated
with shorter OS. In contrast, cord blood transplantation (HR,.56; 95% CI, .31 to .99; P ¼ .045) was associated with longer
OS (Table 3).Pretransplant Factors Associated with High ANG2 at
Transplant
To elucidate the factors associated with a high ANG2 level
at transplant, we performed logistic regression models. The
following potential confounders were adjusted for this
analysis: age (<50 versus 50), sex, disease risk (standard
versus high), disease type (acute myelogenous leukemia/
myelodysplastic syndrome versus other), bone marrow blast
count (10% versus >10%), HCT-CI score (0 to 3 versus >3),
and conditioning regimen (RIC versus myeloablative condi-
tioning and the use of BU, melphalan, or TBI). High bone
marrow blast count at transplant (>10%) was signiﬁcantly
associated with subsequent high ANG2 (2000 pg/mL) at
transplant (P ¼ .034).DISCUSSION
In the present study we found a signiﬁcant association of
high ANG2 level at transplant with the incidence of TRC-EC
and OS. Moreover, ANG2 represented an independent prog-
nostic factor for TRC-EC and OS even after excluding the ef-
fect of other potential confounders. To our knowledge, this is
the ﬁrst study that has evaluated the clinical signiﬁcance of
ANG2 level in predicting TRC-EC. Our ﬁndings suggest that
ANG2 level at transplant can be used as a good biomarker for
TRC-EC in patients undergoing allo-HSCT.
Table 3
Univariate and Multivariate Analyses of Risk Factors for TRC-EC and OS
Variables TRC-EC OS
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age at transplantation
<50 yr 1.00 1.00
50 yr 1.09 .60-1.97 .767 1.32 .82-2.10 .253
Patient sex
Female 1.00 1.00
Male .85 .46-1.58 .624 .95 .58-1.57 .853
Disease
Other 1.00 1.00
AML/MDS 1.02 .54-1.91 .936 1.02 .61-1.69 .942
Disease risk
Standard 1.00 1.00
High 1.55 .86-2.82 .143 .92 .469-1.73 .808 3.12 1.93-5.03 <.001 2.73 1.66-4.48 <.001
BM blast
10% 1.00 1.00
>10% 1.62 .86-3.07 .132 3.26 2.01-5.28 <.001
HCT-CI
3 1.00 1.00
>3 1.29 .51-3.29 .581 1.54 .77-3.11 .225
Conditioning intensity
RIC 1.00 1.00
MAC .60 .32-1.12 .114 1.08 .62-1.89 .783
Conditioning regimen
BU
<8 mg/kg 1.00 1.00
8 mg/kg .57 .22-1.45 .240 .69 .35-1.36 .287
Melphalan
<100 mg/m2 1.00 1.00
100 mg/m2 2.30 1.27-4.16 .006 1.67 1.04-2.69 .036
TBI
<6 Gy 1.00 1.00
6 Gy 1.02 .56-1.85 .929 1.36 .84-2.19 .208
Graft type
Matched donor 1.00 1.00
Mismatched donor 2.82 1.42-5.60 .003 1.99 1.05-3.76 .033 2.04 1.16-3.58 .014
Cord blood 1.11 .52-2.36 .770 .76 .41-1.38 .366 .56 .31-.99 .045
GVHD prophylaxis
Cyclosporine A 1.00 1.00
Tacrolimus 1.77 .087-3.58 .112 1.51 .90-2.53 .117
ANG2 level at transplantation
<2000 1.00 1.00 1.00 1.00
2000 6.52 3.56-11.92 <.001 6.01 3.16-11.43 <.001 2.68 1.64-4.39 <.001 2.23 1.66-4.48 .002
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markers to predict the development of endothelial injury
after allo-HSCT [1]. von Willebrand factor, von Willebrand
factorecleaving protease activity, soluble thrombomodulin,
tumor necrosis factor-a, plasminogen activator inhibitor type
1, and soluble adhesionmolecules (soluble E-selectin, soluble
ICAM-1 [intercellular adhesion molecule-1], soluble vascular
cell adhesion molecule-1 [sVCAM-1]) are the markers most
commonly evaluated. Park et al. [20] showed signiﬁcantly
reduced von Willebrand factorecleaving protease activity in
patients with SOS, even before conditioning. Cutler et al. [21]
concluded that elevations of von Willebrand factor, throm-
bomodulin, and sICAM-1 before and early after HSCT may be
useful for predicting SOS in patients receiving sirolimus.
However, the prognostic values of these reported markers
are not strong enough. Thus, more relevant markers to pre-
dict endothelial injury after allo-HSCT are needed.
Angiopoietin (ANG1 and ANG2) is a family of growth
factors that critically drive vessel growth and shown to play a
major role in the development of endothelial damage in a
variety of diseases. ANG1, a major physiologic ligand for Tie2,
is constitutively provided from perivascular cells and main-
tains endothelial cell survival and quiescence. In contrast,
ANG2 is acutely released from activated endothelial cellsupon stimulation with proinﬂammatory cytokines, proan-
giogenic factors, and hypoxia. ANG2 competitively inhibits
the binding of ANG1 to Tie2, acting as a competitive inhibitor
for ANG1, and renders blood vessels “unstable” [4]. More-
over, along with its functions during angiogenic remodeling,
ANG2 is also reported to be a key molecule in the inﬂam-
matory process. Scholz et al. [22] reported that ANG2 facili-
tates myeloid cell inﬁltration by a b2 integrin dependent
manner. We hypothesized that patients with high ANG2
levels at transplant may be more vulnerable to endothelial
stress, including allogeneic immune reactions or proin-
ﬂammatory cytokines, than patients with low ANG2 levels.
Several groups have reported the prognostic values
of ANG2 especially for GVHD after allo-HSCT. Luft et al. [8]
reported that patients with steroid-refractory GVHD
showed a high ANG2/vascular endothelial growth factor
(VEGF) ratio in comparison with steroid-sensitive aGVHD.
Dietrich et al. [23] reported that pretransplant ANG2 was
predictive for steroid refractoriness within a subset of
patients who developed grades III to IV aGVHD. Another
study of pediatric HSCT demonstrated that pretransplant
ANG2 correlated with the incidence of intestinal GVHD,
whereas post-transplant (day 21) measurements correlated
with the severity of skin and liver GVHD [24].
N. Ueda et al. / Biol Blood Marrow Transplant 20 (2014) 1335e13401340Contrary to these previous reports, our data suggested
that ANG2had no signiﬁcant prognostic effect for grades III to
IV aGVHD.We speculate this inconsistencymay be partly due
to the difference in the extent of prior ANG2 increase between
aGVHD and TRC-EC. We observed a weak but signiﬁcant as-
sociation of ANG2 level with grades III to IV aGVHD at lower
ANG2 cut-off levels (data not shown). Therefore, we presume
that AGN2 may also have some prognostic value for aGVHD.
However, it is notable that the prognostic value of ANG2 level
is far stronger for TRC-EC than for grades III to IV aGVHD.
High ANG2 levels are also reported to be associated with
leukemia relapse after chemotherapy or transplantation
[25,26]. We observed the association of ANG2 with bone
marrow blast counts at transplant. Moreover, high ANG2 was
signiﬁcantly associated with the high relapse rate by uni-
variate analysis. In accordance with these results, high ANG2
was a signiﬁcant factor for OS but not for NRM by multivar-
iate analysis. Shorter OS in patients with high ANG2 may be
attributable to a high relapse rate as well as high NRMmainly
related to TRC-EC.
This study has several limitations. First, all datawere from
a single institute; thus, this research should be validated in a
multicenter trial to minimize any potential center effect.
Second, although we observed signiﬁcant association of
ANG2with the incidence of TRC-EC both in daye5 to e2 and
day e1 to day 3 cohorts, we cannot totally exclude the pos-
sibility that the relatively wide ranges of time for the mea-
surement of ANG2 might affect the results because the
conditioning regimen and the calcineurin inhibitors may
have some effect on ANG2 levels. Third, although we found
consistently high hazard ratios in the high-ANG2 group after
adjusting for potential confounders, the retrospective study
design and heterogeneous background of diseases and
transplantation procedures could also affect the results.
Further investigations are needed to conﬁrm the prognostic
value of ANG2 for TRC-EC.
In conclusion, our study revealed that the high ANG2 level
at transplant was signiﬁcantly associated with the increased
incidence of TRC-EC and poor survival. ANG2 level at trans-
plant could serve as a potential predictive marker for TRC-EC
early after allo-HSCT. A multicenter prospective study is
necessary to validate our ﬁndings.
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